Amniox Medical said yesterday it won reimbursement for its Neox wound matrix umbilical cord allograft through Wisconsin Physicians Service Insurance corp, who will provide Medicare coverage for the treatment for chronic, non-healing wounds.
The WPS Insurance group administers Part A and Part B Medicare benefits for Iowa, Kansas, Missouri, Nebraska, Indiana and Michigan for 4.4 million individuals, the Atlanta-based company said.
“The continued expansion of Medicare coverage illustrates a developing understanding among payers of the clear benefits that our unique products offer, and follows the ongoing adoption among providers. Amniox is committed to developing further access, as well as the clinical evidence that underpins adoption,” CEO Thomas Dugan said in a press release.
Amniox said that Novitas Solutions, Noridian Healthcare Solutions and First Coast Services Options also implemented reimbursement plans for the use of umbilical cord and amniotic membrane products to promote wound healing. The addition of WPS brings the total coverage to more than 60% of individuals covered by Medicare.
Amniox’s parent company, Doral, Fla.-based TissueTech, makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business).
Last month, Amniox Medical released results from a retrospective study of its Neox wound allograft in treating chronic diabetic foot ulcers touting an 87% rate of healing in patients treated with the allograft.
Findings from the study were presented at Superbones Superwounds East 2016 in Teanack, N.J. last week.